Structures by: Cindrić M.
Total: 118
Cis-dioxo(N-3-methoxysalicylidene-2-amino -3- hydroxypyridine)(propanol)molybdenum(VI)
C16H18MoN2O6
CrystEngComm (2011) 13, 13 4314
a=7.7894(4)Å b=10.0907(7)Å c=12.5937(5)Å
α=86.293(4)° β=81.553(4)° γ=69.096(5)°
(4,4'-bipyridine)bis(cis-dioxo(N-3-methoxysalicylidene -2- amino-3-hydroxypyridine))dimolybdenum(VI) dichlormethane solvate
C36H28Mo2N6O10,2(CH2Cl2)
CrystEngComm (2011) 13, 13 4314
a=12.3420(12)Å b=13.4804(9)Å c=17.3437(16)Å
α=90.00° β=131.638(6)° γ=90.00°
Tetrakis[μ~3~-4-methyl-<i>N</i>-(2-oxidophenyl)salicylideneiminato]tetrakis[methanolnickel(II)] methanol 0.8-solvate
C60H60N4Ni4O12,0.8(CH4O)
Acta Crystallographica Section E (2016) 72, 12 1776-1779
a=22.5810(5)Å b=13.7701(3)Å c=18.5242(4)Å
α=90° β=92.125(2)° γ=90°
Tetrakis(μ-thiobenzoato-O,S)bis(triphenylphosphineoxide-O)dimolybdenum(II)
[Mo2(C6H5COS)4],2[(C6H5)3OP]
Acta Crystallographica Section C (1996) 52, 12 3016-3018
a=11.936(2)Å b=20.053(3)Å c=12.306(3)Å
α=90.00° β=93.480(10)° γ=90.00°
Barium decavanadate enneahydrate
Ba3[V10O28],19H2O
Acta Crystallographica Section C (1996) 52, 6 1338-1341
a=9.491(3)Å b=12.201(6)Å c=18.786(12)Å
α=81.27(3)° β=81.02(2)° γ=71.12(2)°
Calcium hydronium decavanadate hexadecahydrate
(Ca2)2,(H3O)2,(V10O286),16(H2O)
Acta Crystallographica Section C (1999) 55, 3 291-293
a=9.7172(6)Å b=10.2638(5)Å c=10.5991(4)Å
α=89.996(4)° β=102.938(4)° γ=110.121(4)°
Dipotassium di-μ-oxo-bis[aqua(oxalato-O^1^,O^2^)oxomolybdenum(III)] trihydrate
2K,C4H4Mo2O142,3H2O
Acta Crystallographica Section C (2000) 56, 6 639-641
a=12.2683(10)Å b=15.0622(17)Å c=18.2824(17)Å
α=81.818(9)° β=71.050(7)° γ=85.001(9)°
Μ-oxo-μ-sulfato-bis[oxotris(isothiocyanato)molybdate(V)]
4C5H6N1,C6Mo2N6O7S74
Acta Crystallographica Section C (1994) 50, 9 1396-1399
a=8.2200(10)Å b=12.491(6)Å c=40.14(2)Å
α=93.45(2)° β=95.13(4)° γ=96.44(2)°
Tetramethylammonium di-chloro-di-μ~2~-oxo-tetra-μ~2~-methoxotetradioxo -tetramolybdate(VI)
2((CH3)4N),(Mo4O10(OCH3)4Cl22)
Acta Crystallographica Section C (2000) 56, 10 e443-e444
a=8.810(2)Å b=11.047(2)Å c=15.085(3)Å
α=90.00° β=98.67(3)° γ=90.00°
Tetramethylammonium hexamolybdate hydrate
2C4H12N1,Mo6O192,H2O
Acta Crystallographica Section C (2000) 56, 7 e278-e279
a=13.824(5)Å b=13.824(5)Å c=13.824(5)Å
α=90.00° β=90.00° γ=90.00°
Salicylaldehyde 4-phenylthiosemicarbazone
C14H13N3OS
Acta Crystallographica Section C (2008) 64, 10 o570-o573
a=10.6328(3)Å b=11.1114(3)Å c=12.8839(10)Å
α=75.251(5)° β=65.652(2)° γ=81.539(2)°
4-methoxysalicylaldehyde 4-phenylthiosemicarbazone
C15H15N3O2S1
Acta Crystallographica Section C (2008) 64, 10 o570-o573
a=4.73851(17)Å b=11.3244(4)Å c=14.0775(5)Å
α=78.390(3)° β=89.547(3)° γ=89.364(3)°
1-{2-[(2-Hydroxy-4-methoxy-benzylidene)-hydrazono]-4-methyl-3-phenyl- -2,3-dihydro-thiazol-5-yl}-ethanone
C20H19N3O3S
Crystal Growth & Design (2011) 11, 12 5227
a=9.5280(4)Å b=10.0721(4)Å c=10.5449(3)Å
α=95.344(3)° β=110.811(4)° γ=95.371(4)°
Ethoxo-(4-methoxysalicylaldehyde-4-phenylthiosemicarbazonato(2-))- oxo-vanadium(V)
C17H18N3O4SV
Crystal Growth & Design (2011) 11, 12 5227
a=12.4255(3)Å b=15.7746(4)Å c=18.5559(5)Å
α=90.00° β=96.510(2)° γ=90.00°
Propoxo-(4-methoxysalicylaldehyde-4-phenylthiosemicarbazonato(2-))- oxo-vanadium(V)
C18H20N3O4SV
Crystal Growth & Design (2011) 11, 12 5227
a=12.3684(3)Å b=15.9862(4)Å c=19.1848(5)Å
α=90.00° β=97.975(2)° γ=90.00°
Propoxo-(4-methoxysalicylaldehyde-4-phenylthiosemicarbazonato(2-))- oxo-vanadium(V)
C18H20N3O4SV
Crystal Growth & Design (2011) 11, 12 5227
a=9.7545(11)Å b=12.9941(14)Å c=30.452(3)Å
α=88.183(8)° β=80.838(9)° γ=89.875(9)°
Methoxo-(4-methoxysalicylaldehyde-4-phenylthiosemicarbazonato(2-))- oxo-vanadium(V)
C16H16N3O4SV
Crystal Growth & Design (2011) 11, 12 5227
a=12.2897(5)Å b=10.3757(4)Å c=16.3811(9)Å
α=90.00° β=125.598(3)° γ=90.00°
Ethoxo-(4-methoxysalicylaldehyde-4-phenylthiosemicarbazonato(2-))- oxo-vanadium(V)
C17H18N3O4SV
Crystal Growth & Design (2011) 11, 12 5227
a=7.2239(11)Å b=9.693(2)Å c=13.592(3)Å
α=87.323(18)° β=86.732(15)° γ=71.447(17)°